224 studies

BioGaia contributes to increased knowledge of probiotics. 14% of the company net sales is devoted to research and development. The efficacy and safety of BioGaia’s different strains of L. reuteri have been documented in 224 clinical studies in around 18,000 people of all ages.



78% Pediatrics

BioGaia offers consumers probiotic products that contribute to improved health



157 Employees in the Group

BioGaia offers its employees a meaningful and stimulating workplace where employees feel job satisfaction



Distribution in more than 100 countries

BioGaia builds long-term relationships with distributors and supports them within sales and marketing


Share holders

4% Growth 32% Operating margin

Through good risk management and a long-term strategy BioGaia offers a stable value appreciation for its shareholders